US National Institutes of Health: The Role of Epitranscriptomics in Development and Disease (R21 – Clinical Trial Not Allowed)

This opportunity uses the R01 Research Project Grant funding mechanism.

Funding Opportunity Announcement (FOA) Number: PAR-18-831

The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications for its role of epitranscriptomics in development and disease (R21 clinical trial not allowed) funding opportunity.

This supports research into the role of RNA chemical modifications in the initiation and progression of various developmental processes and disease states and conditions relevant to the institute.

Companion Schemes

  • PAR-18-830, R01 Research Project Grant

Funding & Duration

The number of awards is contingent on NIH appropriations and the submission of a sufficient number of meritorious applications.

The combined budget for direct costs for the two-year project period may not exceed USD $275,000 (approx AUD $371,000).

No more than USD $200,000 (approx. AUD $270,000) may be requested in any single year.


Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.

Submission Requirements & Due Date

Further Information

Need Help?

This entry was posted in Engineering, Computer & Mathematical Sciences, Funding by Award Type, Grants (Project Funds), International Funding, Professions, Sciences and tagged . Bookmark the permalink.

Comments are closed.